| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,424 |
2,328 |
$158K |
| 96401 |
|
3,491 |
2,998 |
$147K |
| 94060 |
|
3,356 |
3,142 |
$81K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,620 |
1,407 |
$61K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
387 |
377 |
$54K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
582 |
577 |
$52K |
| 95117 |
|
1,885 |
700 |
$14K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,358 |
1,183 |
$10K |
| 36415 |
Collection of venous blood by venipuncture |
499 |
491 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
36 |
34 |
$812.53 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
15 |
15 |
$552.24 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
42 |
41 |
$369.21 |
| 70210 |
|
14 |
14 |
$242.11 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
19 |
16 |
$77.68 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
27 |
27 |
$0.12 |
| J2357 |
Injection, omalizumab, 5 mg |
2,416 |
2,187 |
$0.00 |